pone.0248034.g001.tif (1.61 MB)
Representative RORγt inhibitors (Compounds 1–3) and inverse agonist, SR2211.
figure
posted on 2021-11-09, 18:32 authored by Steven A. Saenz, Andrea Local, Tiffany Carr, Arvind Shakya, Shivsmriti Koul, Haiqing Hu, Lisa Chourb, Justin Stedman, Jenna Malley, Laura Akullian D’Agostino, Veerabahu Shanmugasundaram, John Malona, C. Eric Schwartz, Lisa Beebe, Meghan Clements, Ganesh Rajaraman, John Cho, Lan Jiang, Alex Dubrovskiy, Matt Kreilein, Roman Shimanovich, Lawrence G. Hamann, Laure Escoubet, J. Michael EllisStructures of Compounds 1–3 compared to inverse agonist, SR2211 (A) and chemical synthesis route for Compound 3 (B).
History
Usage metrics
Categories
Keywords
retinoic acid receptorpancreatic ductal adenocarcinomadiv >< pattractive therapeutic targetassociated gene expressionnumerous autoimmune diseasesdelay tumor volumeinhibit th17 differentiationinhibit tumor formationrorγt block th17tumor formationautoimmune disorderstumor growthtumor effectsth17 cellsvivo vitro transcription factorsrorγt inhibitorsrorγt functionsprimary functionpreclinical modelsimmune responsesdependent mannercritical regulator17a production
Licence
Exports
RefWorks
BibTeX
Ref. manager
Endnote
DataCite
NLM
DC